Natixis Advisors LLC increased its stake in Elevance Health, Inc. (NYSE:ELV – Free Report) by 9.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 267,062 shares of the company’s stock after buying an additional 22,267 shares during the quarter. Natixis Advisors LLC’s holdings in Elevance Health were worth $93,619,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Sound View Wealth Advisors Group LLC grew its stake in shares of Elevance Health by 3.0% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock worth $354,000 after buying an additional 29 shares during the last quarter. Fulton Breakefield Broenniman LLC grew its stake in shares of Elevance Health by 3.6% in the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock worth $289,000 after buying an additional 29 shares during the last quarter. Perigon Wealth Management LLC grew its stake in shares of Elevance Health by 2.2% in the 4th quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock worth $481,000 after buying an additional 29 shares during the last quarter. Savvy Advisors Inc. grew its stake in shares of Elevance Health by 3.2% in the 4th quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock worth $343,000 after buying an additional 30 shares during the last quarter. Finally, CoreCap Advisors LLC grew its stake in shares of Elevance Health by 6.1% in the 4th quarter. CoreCap Advisors LLC now owns 557 shares of the company’s stock worth $195,000 after buying an additional 32 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on ELV shares. Truist Financial upped their price target on Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a research note on Monday. Sanford C. Bernstein upped their price objective on Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a research report on Friday, April 24th. Leerink Partners set a $364.00 price objective on Elevance Health in a research report on Thursday, April 23rd. Weiss Ratings raised Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, May 18th. Finally, JPMorgan Chase & Co. upped their price objective on Elevance Health from $397.00 to $411.00 and gave the company an “overweight” rating in a research report on Tuesday, April 28th. Fourteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $407.05.
Elevance Health Stock Performance
ELV stock opened at $388.33 on Wednesday. The stock’s 50 day simple moving average is $345.97 and its 200 day simple moving average is $339.77. The stock has a market capitalization of $84.33 billion, a PE ratio of 16.52, a price-to-earnings-growth ratio of 2.28 and a beta of 0.67. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $408.00.
Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.74 by $1.84. The firm had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company’s revenue was up 1.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, research analysts forecast that Elevance Health, Inc. will post 26.94 earnings per share for the current fiscal year.
Elevance Health Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 29.26%.
Elevance Health Company Profile
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
Read More
- Five stocks we like better than Elevance Health
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.png){kind=logo}